FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Fillit of Type Response	3)																	
1. Name and Address of Reporting Person* Petree Daniel H				2. Issuer Name and Ticker or Trading Symbol SUTRO BIOPHARMA INC [STRO]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) C/O SUTRO BIOF AVENUE, SUITE		NC., 310 UTAH		Date of E /01/20		est Ti	ransact	ion (N	Ionth/D	ay/Year)			Officer (g	ive title below)		Other (sp	ecify below)	
(Street)				4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) X Form filed by One Reporting Person						
SOUTH SAN FRANCISCO, CA 94080											_	Form filed by More than One Reporting Person						
(City)	(State)	(Zip)				Та	ble I -	Non-	Derivat	ive Secur	ities A	cquire	d, Dispose	d of, or Ber	neficially	Owned		
1.Title of Security (Instr. 3)		Date (Month/Day/Year) E		2A. Deemed Execution Date any (Month/Day/Y	Date, if C		3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)					wned Following saction(s)		6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
							Code	V	Amour	(A) or (D)	Price	(,	or (I)		Indirect	(Instr. 4)	
Common Stock		10/01/2018					M		314	A	\$ 5.81	314	4		I		Daniel H. Petree and Susan M. Toeniskoetter Trust dated July 25, 1997	
Common Stock		10/01/2018				:	S ⁽²⁾		122	D	\$ 15	192	I			Daniel H. Petree and Susan M. Toeniskoetter Trust dated July 25, 1997		
Reminder: Report on a	separate line for							Pe co fo	ersons ontaine rm disp	who res d in this	form a	are no tly vali	t require d OMB c	n of inform d to respo ontrol nun	nd unles	ss the	SEC 147	74 (9-02)
						, wai		optio	ns, con	vertible s	ecuriti	es)			I			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transactic Date (Month/Day Security)		Execution Date,		e, if Transaction Code ear) (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		and Expiration Date (Month/Day/Year)			of U Secu	7. Title and Amount of Underlying Securities (Instr. 3 and 4)		Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported	ve Constant of the constant of	Ownership Form of Derivative Security: Direct (D) or Indirect	Beneficia
				Code	v	(A)	(D)	Date Exer	cisable	Expiratio Date	n Title	e	Amount or Number of Shares					
Common Stock Warrant (right to buy) \$ 5.81 (3)	10/01/20	18		М			314		<u>(4)</u>	(4)		mmon tock	314	\$ 0	0		D	

Reporting Owners

Relationships

Reporting Owner Name / Address	Director	10% Owner	Officer	Other
Petree Daniel H C/O SUTRO BIOPHARMA, INC. 310 UTAH AVENUE, SUITE 150 SOUTH SAN FRANCISCO, CA 94080	X			

Signatures

/s/ Edward C. Albini as attorney-in-fact for Daniel H. Petree	10/01/2018		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These securities are held of record by the reporting person and his spouse as trustees of the Daniel H. Petree and Susan M. Toeniskoetter Trust dated July 25, 1997.
- On October 1, 2018, the reporting person exercised a warrant to purchase 314 shares of issuer's common stock for \$5.81 per share. The reporting person paid the exercise price on a cashless basis, resulting in the issuer withholding 122 of the shares to pay the exercise price and issuing to the reporting person the remaining 192 shares.
- The warrant has a net exercise provision under which the holder, in lieu of paying the exercise price in cash, can surrender the warrant and receive a net number of shares of common stock based on the fair market value of such stock at the time of exercise, after deducting the aggregate exercise price.
- (4) The warrant is exercisable at any time at the holder's election on a one-for one basis and automatically terminates on the completion of the issuer's initial public offering if not earlier exercised.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.